Biogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment
Biogen halts study of closely watched Alzheimer’s drug, a blow to hopes for new treatment.
by Adam Feuerstein
Mar 21, 2019
1 minute
Alzheimer’s disease has beaten back another effort to tame it.
Biogen and its Japanese pharma partner Eisai said Thursday that they were halting two Phase 3 clinical trials of aducanumab, a drug that was designed to slow the worsening of Alzheimer’s by known as beta-amyloid.
You’re reading a preview, subscribe to read more.
Start your free 30 days